Aadi Bioscience (AADI) stock Forecast for 2022 – 2026
Last update: October 6, 2022 (17:30)Sector: Healthcare
The share price of Aadi Bioscience, Inc. (AADI) now
What analysts predict: $43.5
52-week high/low: $32.5 / $11
50/200 Day Moving Average: $13.19 / $16.19
This figure corresponds to the average price over the previous 50/200 days. For Aadi Bioscience stocks, the 50-day moving average is the support level today.
For Aadi Bioscience stocks, the 200-day moving average is the resistance level today.
Are you interested in Aadi Bioscience, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Aadi Bioscience stock price in 2022, 2023, 2024, 2025, 2026. How much will one Aadi Bioscience share be worth in 2022 - 2026?
When should I take profit in Aadi Bioscience stock? When should I record a loss on Aadi Bioscience stock? What are analysts' forecasts for Aadi Bioscience stock? What is the future of Aadi Bioscience stock?
We forecast Aadi Bioscience stock performance using neural networks based on historical data on Aadi Bioscience stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Aadi Bioscience stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Aadi Bioscience shares. This happens once a day.
Fresh insight into Aadi Bioscience stockView all analytics
Summary Shares have lost half their value since reverse merger with Aerpio Pharmaceuticals. Aadi aims to deliver on the broad potential of mTOR inhibition via nab technology to achieve wide … Read more
Summary Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa. Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; … Read more
Historical and forecast chart of Aadi Bioscience stock
The chart below shows the historical price of Aadi Bioscience stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Aadi Bioscience stock price can be found in the table below.
Long-term forecasts by years.
Aadi Bioscience daily forecast for a month
Aadi Bioscience Daily Price Targets
Aadi Bioscience Stock Forecast 10-08-2022.
Pessimistic target level: 14.22
Optimistic target level: 14.95
Aadi Bioscience Stock Forecast 10-09-2022.
Pessimistic target level: 13.98
Optimistic target level: 14.87
Aadi Bioscience Stock Forecast 10-10-2022.
Pessimistic target level: 13.68
Optimistic target level: 14.41
Aadi Bioscience Stock Forecast 10-11-2022.
Pessimistic target level: 13.23
Optimistic target level: 14.04
Aadi Bioscience Stock Forecast 10-12-2022.
Pessimistic target level: 13.54
Optimistic target level: 14.42
Aadi Bioscience Stock Forecast 10-13-2022.
Pessimistic target level: 13.35
Optimistic target level: 14.02
AADI (AADI) Monthly Stock Prediction for 2022
Aadi Bioscience forecast for this year
Aadi Bioscience Stock Prediction for Nov 2022
An uptrend is forecast for this month with an optimal target price of $16.2564. Pessimistic: $14.37. Optimistic: $18.27
Aadi Bioscience Stock Prediction for Dec 2022
An downtrend is forecast for this month with an optimal target price of $15.281. Pessimistic: $14.30. Optimistic: $16.93
Aadi Bioscience (AADI) Monthly Stock Prediction for 2023
Aadi Bioscience (AADI) Monthly Stock Prediction for 2024
Aadi Bioscience (AADI) Monthly Stock Prediction for 2025
Aadi Bioscience (AADI) Monthly Stock Prediction for 2026
Aadi Bioscience information and performance
Aadi Bioscience, Inc, formerly Aerpio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing precision therapies for genetically defined cancers. It develops therapies for cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. Its lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models2. Its nab platform allows for intratumoral drug accumulation and mTOR target suppression (pS6) at equal doses for FYARROTM vs oral mTOR inhibitors resulting in higher anti-tumor activity in animal models. Its product, FYARROTM, is in phase II registrational trial for nab-sirolimus, ABI-009 in patients with advanced perivascular epithelioid cell tumors (PEComa).
Aadi Bioscience Address
9987 CARVER ROAD, CINCINNATI, OH, US
Market Capitalization: 294 025 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -57 346 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 18.23
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 26.69
Enterprise Value (EV) /Revenue
EV To EBITDA: -1.337
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 21016800
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.